← Back to Search

Genetic Testing

Cancer Treatment for Cancer

N/A

Waitlist Available

Research Sponsored by New Mexico Cancer Care Alliance

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Any patient with a malignant diagnosis at the time of diagnosis or relapse

Must not have

Adults not able to consent for themselves are excluded from participation

Subjects for whom sufficient cancer tissues are not available to meet the objectives of the study

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 years

Awards & highlights

No Placebo-Only Group

Summary

This trial will test a new system for genomically tailoring cancer care at the University of New Mexico Cancer Center. The system will use special tests based on patients' genetic makeup to better guide cancer care decisions.

Who is the study for?

This trial is open to anyone diagnosed with cancer at any stage or age, including pregnant women and those with non-cancer genetic disorders. Participants must be able to understand and sign consent forms; however, cognitively impaired adults, those unable to consent for themselves, prisoners, and subjects without enough cancer tissue samples are excluded.

What is being tested?

The study aims to develop a local system that uses genome sequencing of patients' tumor tissues compared to normal tissues. This personalized medicine approach seeks to identify genetic changes guiding more effective treatment options based on individual genetic profiles.

What are the potential side effects?

Since this trial involves genomic testing rather than drug interventions, traditional side effects are not applicable. However, there may be psychological impacts from learning about one's genetic predispositions towards various conditions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with cancer or my cancer has returned.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am able to give my own consent to participate.

Select...

I do not have enough cancer tissue samples for study purposes.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Number of patients with clinically actionable findings

Secondary study objectives

Frequency of findings (CAF) in cancer patients treated locally

Number of barriers limiting use of genomics information in local patient care

Percentage of patients with secondary findings (SF)

+2 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Cancer Treatment OptionsExperimental Treatment1 Intervention

Blood samples and, for some patients, buccal (mouth cell) samples will be collected at diagnosis and/or relapse. Solid tumor samples will be collected in the normal course of treatment, from biopsy, blood or other specimens. For blood-based cancers such as leukemia, blood and bone marrow specimens will be collected before treatment begins, on day 29 and possibly at a later time point if relapse occurs.

0 / 3Eligibility criteria met